The dilemma is heart-rending. With COVID-19 infections and hospitalizations rising, the FDA approved two drugs—Paxlovid from Pfizer, and molnupiravir from Merck and Ridgeback—to treat the illness that is killing so many and rendering others permanently disabled. Yet in the United States, many patients can’t get the drug, or even figure out which pharmacy near them […]
Subscribe to:
Post Comments (Atom)
< + > Provider Enrollment is a Data Problem Hiding in the Denial Queue
The following is a guest article by Madison Gardner, President at AMS Solutions, Inc. A claim can pass every check a practice controls and ...
No comments:
Post a Comment